APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Cytomegalovirus Envelope Glycoprotein B

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Cytomegalovirus Envelope Glycoprotein B Market Outlook and Growth Opportunities 2026

26 December 2025193 pages

Choose your research edition.

Industry ResearchHuman Cytomegalovirus Envelope Glycoprotein B Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Cytomegalovirus Envelope Glycoprotein B Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Human Cytomegalovirus Envelope Glycoprotein B Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Cytomegalovirus Envelope Glycoprotein B Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Cytomegalovirus Envelope Glycoprotein B Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Human Cytomegalovirus Envelope Glycoprotein B market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Cytomegalovirus Envelope Glycoprotein B is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Cytomegalovirus Envelope Glycoprotein B is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Cytomegalovirus Envelope Glycoprotein B is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Cytomegalovirus Envelope Glycoprotein B market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Cytomegalovirus Envelope Glycoprotein B market include Vical Incorporated, VBI Vaccine Inc, Vakzine Projekt Management GmbH, Trellis Bioscience, Inc. and Astellas Pharma Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Cytomegalovirus Envelope Glycoprotein B market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Cytomegalovirus Envelope Glycoprotein B and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Cytomegalovirus Envelope Glycoprotein B sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Cytomegalovirus Envelope Glycoprotein B market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Cytomegalovirus Envelope Glycoprotein B Segment by Company

Vical Incorporated

VBI Vaccine Inc

Vakzine Projekt Management GmbH

Trellis Bioscience, Inc.

Astellas Pharma Inc.

Human Cytomegalovirus Envelope Glycoprotein B Segment by Type

CSJ-148

CyMVectin

PPCM

TRL-345

Cytomegalovirus Vaccine

Others

Human Cytomegalovirus Envelope Glycoprotein B Segment by Application

Infectious Disease

Women's Health

Oncology

Others

Human Cytomegalovirus Envelope Glycoprotein B Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Cytomegalovirus Envelope Glycoprotein B status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Cytomegalovirus Envelope Glycoprotein B market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Cytomegalovirus Envelope Glycoprotein B significant trends, drivers, influence factors in global and regions.

6. To analyze Human Cytomegalovirus Envelope Glycoprotein B competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Cytomegalovirus Envelope Glycoprotein B market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Cytomegalovirus Envelope Glycoprotein B and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Cytomegalovirus Envelope Glycoprotein B.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Cytomegalovirus Envelope Glycoprotein B market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Cytomegalovirus Envelope Glycoprotein B industry.

Chapter 3: Detailed analysis of Human Cytomegalovirus Envelope Glycoprotein B manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Cytomegalovirus Envelope Glycoprotein B in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Cytomegalovirus Envelope Glycoprotein B in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Cytomegalovirus Envelope Glycoprotein B Industry Trends Table 2. Human Cytomegalovirus Envelope Glycoprotein B Industry Drivers Table 3. Human Cytomegalovirus Envelope Glycoprotein B Industry Opportunities and Challenges Table 4. Human Cytomegalovirus Envelope Glycoprotein B Industry Restraints Table 5. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Share by Company (2021-2026) Table 7. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume Share by Company (2021-2026) Table 9. Global Human Cytomegalovirus Envelope Glycoprotein B Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Human Cytomegalovirus Envelope Glycoprotein B Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Cytomegalovirus Envelope Glycoprotein B Key Company Manufacturing Base & Headquarters Table 12. Global Human Cytomegalovirus Envelope Glycoprotein B Company, Product Type & Application Table 13. Global Human Cytomegalovirus Envelope Glycoprotein B Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Cytomegalovirus Envelope Glycoprotein B by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of CSJ-148 Table 18. Significant Companies of CyMVectin Table 19. Significant Companies of PPCM Table 20. Significant Companies of TRL-345 Table 21. Significant Companies of Cytomegalovirus Vaccine Table 22. Significant Companies of Others Table 23. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 24. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Type (2021-2026) & (W Units) Table 25. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Type (2027-2032) & (W Units) Table 26. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume Share by Type (2021-2026) Table 27. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume Share by Type (2027-2032) Table 28. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type (2021-2026) Table 32. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Infectious Disease Table 34. Significant Companies of Women's Health Table 35. Significant Companies of Oncology Table 36. Significant Companies of Others Table 37. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 38. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Application (2021-2026) & (W Units) Table 39. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Application (2027-2032) & (W Units) Table 40. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume Share by Application (2021-2026) Table 41. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume Share by Application (2027-2032) Table 42. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application (2021-2026) Table 46. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application (2027-2032) Table 47. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 48. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region (2021-2026) & (W Units) Table 49. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Region (2021-2026) Table 50. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region (2027-2032) & (W Units) Table 51. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Region (2027-2032) Table 52. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Region (2021-2026) Table 55. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Region (2027-2032) Table 57. Global Human Cytomegalovirus Envelope Glycoprotein B Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Human Cytomegalovirus Envelope Glycoprotein B Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2026) & (W Units) Table 62. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Country (2021-2026) Table 63. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2027-2032) & (W Units) Table 64. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Country (2027-2032) Table 65. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Market Share by Country (2021-2026) Table 67. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Market Share by Country (2027-2032) Table 69. Vical Incorporated Company Information Table 70. Vical Incorporated Business Overview Table 71. Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio Table 73. Vical Incorporated Recent Development Table 74. VBI Vaccine Inc Company Information Table 75. VBI Vaccine Inc Business Overview Table 76. VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio Table 78. VBI Vaccine Inc Recent Development Table 79. Vakzine Projekt Management GmbH Company Information Table 80. Vakzine Projekt Management GmbH Business Overview Table 81. Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio Table 83. Vakzine Projekt Management GmbH Recent Development Table 84. Trellis Bioscience, Inc. Company Information Table 85. Trellis Bioscience, Inc. Business Overview Table 86. Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio Table 88. Trellis Bioscience, Inc. Recent Development Table 89. Astellas Pharma Inc. Company Information Table 90. Astellas Pharma Inc. Business Overview Table 91. Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio Table 93. Astellas Pharma Inc. Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. Human Cytomegalovirus Envelope Glycoprotein B Distributors List Table 97. Human Cytomegalovirus Envelope Glycoprotein B Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Human Cytomegalovirus Envelope Glycoprotein B Product Image Figure 2. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Cytomegalovirus Envelope Glycoprotein B Sales (2021-2032) & (W Units) Figure 5. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Human Cytomegalovirus Envelope Glycoprotein B Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. CSJ-148 Image Figure 10. CyMVectin Image Figure 11. PPCM Image Figure 12. TRL-345 Image Figure 13. Cytomegalovirus Vaccine Image Figure 14. Others Image Figure 15. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume Share by Type (2021-2032) Figure 18. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type (2021-2032) Figure 21. Infectious Disease Image Figure 22. Women's Health Image Figure 23. Oncology Image Figure 24. Others Image Figure 25. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume Share by Application (2021-2032) Figure 28. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application (2021-2032) Figure 31. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 32. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2021-2032) & (US$ Million) Figure 36. North America Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2021-2032) & (US$ Million) Figure 42. South America Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Human Cytomegalovirus Envelope Glycoprotein B Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Human Cytomegalovirus Envelope Glycoprotein B Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • CSJ-148
  • CyMVectin
  • PPCM
  • TRL-345
  • Cytomegalovirus Vaccine
  • Others
Applications
  • Infectious Disease
  • Women's Health
  • Oncology
  • Others
Companies covered
  • Vical Incorporated
  • VBI Vaccine Inc
  • Vakzine Projekt Management GmbH
  • Trellis Bioscience, Inc.
  • Astellas Pharma Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2021-2032)
  4. 1.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume (2021-2032)
  5. 1.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Cytomegalovirus Envelope Glycoprotein B Market Dynamics
  1. 2.1 Human Cytomegalovirus Envelope Glycoprotein B Industry Trends
  2. 2.2 Human Cytomegalovirus Envelope Glycoprotein B Industry Drivers
  3. 2.3 Human Cytomegalovirus Envelope Glycoprotein B Industry Opportunities and Challenges
  4. 2.4 Human Cytomegalovirus Envelope Glycoprotein B Industry Restraints
3 Human Cytomegalovirus Envelope Glycoprotein B Market by Company
  1. 3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Company Revenue Ranking in 2025
  2. 3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Company (2021-2026)
  3. 3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Cytomegalovirus Envelope Glycoprotein B Average Price by Company (2021-2026)
  5. 3.5 Global Human Cytomegalovirus Envelope Glycoprotein B Company Ranking (2024-2026)
  6. 3.6 Global Human Cytomegalovirus Envelope Glycoprotein B Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Cytomegalovirus Envelope Glycoprotein B Company Product Type and Application
  8. 3.8 Global Human Cytomegalovirus Envelope Glycoprotein B Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Cytomegalovirus Envelope Glycoprotein B Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Cytomegalovirus Envelope Glycoprotein B Market by Type
  1. 4.1 Human Cytomegalovirus Envelope Glycoprotein B Type Introduction
  2. 4.1.1 CSJ-148
  3. 4.1.2 CyMVectin
  4. 4.1.3 PPCM
  5. 4.1.4 TRL-345
  6. 4.1.5 Cytomegalovirus Vaccine
  7. 4.1.6 Others
  8. 4.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Type
  9. 4.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type
  13. 4.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (2021-2032)
  15. 4.3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type (2021-2032)
5 Human Cytomegalovirus Envelope Glycoprotein B Market by Application
  1. 5.1 Human Cytomegalovirus Envelope Glycoprotein B Application Introduction
  2. 5.1.1 Infectious Disease
  3. 5.1.2 Women's Health
  4. 5.1.3 Oncology
  5. 5.1.4 Others
  6. 5.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Application
  7. 5.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application
  11. 5.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application (2021-2032)
  13. 5.3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application (2021-2032)
6 Human Cytomegalovirus Envelope Glycoprotein B Regional Sales and Value Analysis
  1. 6.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region (2021-2032)
  3. 6.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2021-2026
  4. 6.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region (2027-2032)
  5. 6.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region (2027-2032)
  9. 6.5 Global Human Cytomegalovirus Envelope Glycoprotein B Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2021-2032)
  12. 6.6.2 North America Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2021-2032)
  15. 6.7.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2021-2032)
  21. 6.9.2 South America Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country, 2025 VS 2032
7 Human Cytomegalovirus Envelope Glycoprotein B Country-level Sales and Value Analysis
  1. 7.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2032)
  4. 7.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2026)
  5. 7.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2027-2032)
  6. 7.4 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Vical Incorporated
  2. 8.1.1 Vical Incorporated Company Information
  3. 8.1.2 Vical Incorporated Business Overview
  4. 8.1.3 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
  6. 8.1.5 Vical Incorporated Recent Developments
  7. 8.2 VBI Vaccine Inc
  8. 8.2.1 VBI Vaccine Inc Company Information
  9. 8.2.2 VBI Vaccine Inc Business Overview
  10. 8.2.3 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
  12. 8.2.5 VBI Vaccine Inc Recent Developments
  13. 8.3 Vakzine Projekt Management GmbH
  14. 8.3.1 Vakzine Projekt Management GmbH Company Information
  15. 8.3.2 Vakzine Projekt Management GmbH Business Overview
  16. 8.3.3 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
  18. 8.3.5 Vakzine Projekt Management GmbH Recent Developments
  19. 8.4 Trellis Bioscience, Inc.
  20. 8.4.1 Trellis Bioscience, Inc. Company Information
  21. 8.4.2 Trellis Bioscience, Inc. Business Overview
  22. 8.4.3 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
  24. 8.4.5 Trellis Bioscience, Inc. Recent Developments
  25. 8.5 Astellas Pharma Inc.
  26. 8.5.1 Astellas Pharma Inc. Company Information
  27. 8.5.2 Astellas Pharma Inc. Business Overview
  28. 8.5.3 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
  30. 8.5.5 Astellas Pharma Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Cytomegalovirus Envelope Glycoprotein B Value Chain Analysis
  2. 9.1.1 Human Cytomegalovirus Envelope Glycoprotein B Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Cytomegalovirus Envelope Glycoprotein B Sales Mode & Process
  6. 9.2 Human Cytomegalovirus Envelope Glycoprotein B Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Cytomegalovirus Envelope Glycoprotein B Distributors
  9. 9.2.3 Human Cytomegalovirus Envelope Glycoprotein B Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst